Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis

Manzano-Robleda, María del Carmen; Ornelas-Arroyo, Victoria J.; Barrientos‐Gutiérrez, Tonatiuh; Méndez-Sánchez, Nahúm; Uribe, Misael; Chávez-Tapia, Norberto C.

doi:10.1016/s1665-2681(19)30800-2

Cited by 19 publications

(9 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although triple therapy was associated with higher SVR rates than dual therapy in all patient subgroups, significant advantage was observed for treatment‐experienced patients, patients with IL28B genotype CT or TT, HCV genotype 1b, high pretreatment viral load, early fibrosis, platelet count > 150 000/μL and elevated ALT levels (Box ). Overall, the ratio of odds ratios indicated that treatment‐experienced patients, as already observed , and patients with elevated ALT levels showed maximum benefit from triple therapy. It is interesting to note that several factors associated with an increased rate of SVR to triple therapy represent negative predictors of response to dual therapy, such as previous unsuccessful treatment, IL28B CT/TT, high viral load .…”

Section: Discussionsupporting

confidence: 70%

Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review

Pecoraro

Cariani

Villa³

et al. 2016

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 70%

Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review

Pecoraro

Cariani

Villa³

et al. 2016

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…In May 2011, the FDA approved the first class of DAAs (NS3/4a protease inhibitors) for use with PEG IFN and RBV as triple therapy. While the SVR rates dramatically improved to 60–80%, therapy was still complicated by a cumbersome treatment protocol with numerous side effects, including, but not limited to, rash, anemia, thrombocytopenia and fatigue .…”

Section: Discussionmentioning

confidence: 99%

Long term survival in persons with hemophilia and chronic hepatitis C: 40 year outcomes of a large single center cohort

Eyster

Kong

et al. 2016

American J Hematol

View full text Add to dashboard Cite

We studied the course of chronic HCV infections in a cohort of 222 persons with hemophilia (PWH) and von Willebrand disease followed at our center since 1973. Twenty two (10%) developed end stage liver disease (ESLD). Forty years after HCV infection, cumulative incidence of ESLD was 12.3% and overall survival was 45.5%. Those who were infected with HCV only (n=100) had a survival of 75.2%, while those infected with HIV (n=122) had a survival of 24% (P<.001). Survivals were significantly longer for those infected with HCV at younger age (< 15 years) compared to those infected over age 30 years (P=0.014). Cause specific deaths for ESLD and bleeding were 8.8% and 8.3% respectively. For HIV negative subjects, the annual hazard of death from ESLD and bleeding was near zero for the first 10 years, and then rose slowly over the next 20 years to 0.4/100py for ESLD and 0.2/100py for bleeding. Sixty subjects completed 79 treatment episodes. Sustained viral response rates increased from 7/21 (33%) between 1990-2001, to 17/29 (58%) between 2002-2011, and to 27/29 (93%), since 2012 with the advent of the directly acting antiviral agents. These results confirm the very slow ESLD progression rate in HIV negative PWH. However, the risk of death from both ESLD and bleeding increases steadily with longer duration of HCV infection. More aggressive surveillance to detect those with early fibrosis is needed now that curative treatment is possible in >95% of individuals.

show abstract

“…The pharmacological data justify maintaining a close monitoring of HIV-VL for patients treated with an ATV/r-based regimen, and a shorter regimen might be considered for patients with RVR8. Such a therapeutic option might be considered in countries where treatment of hepatitis C infection with the newer direct-acting antiviral drugs remains difficult because of the lack of availability, as recently emphasized 15 .…”

Section: Discussionmentioning

confidence: 99%

Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study

Poizot‐Martin

Garraffo

Colson

et al. 2016

HIV Clinical Trials

View full text Add to dashboard Cite

show abstract

Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis

Cited by 19 publications

References 39 publications

Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review

Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review

Long term survival in persons with hemophilia and chronic hepatitis C: 40 year outcomes of a large single center cohort

Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study

Contact Info

Product

Resources

About